Last reviewed · How we verify
Placebo + R-CHOP
This is a Phase 3 trial comparing placebo against R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), a standard chemotherapy regimen that combines a CD20-targeting monoclonal antibody with multi-agent chemotherapy to treat B-cell lymphomas.
This is a Phase 3 trial comparing placebo against R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), a standard chemotherapy regimen that combines a CD20-targeting monoclonal antibody with multi-agent chemotherapy to treat B-cell lymphomas. Used for B-cell non-Hodgkin lymphoma (specific subtype not specified in available information).
At a glance
| Generic name | Placebo + R-CHOP |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Drug class | Monoclonal antibody + multi-agent chemotherapy combination |
| Target | CD20 (rituximab component); multiple targets (CHOP chemotherapy) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
R-CHOP is a combination regimen where rituximab (a chimeric anti-CD20 monoclonal antibody) targets CD20 on B-cell surfaces to induce cell death, while CHOP chemotherapy agents work through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and mitotic arrest. The trial design uses placebo as a control arm to evaluate the efficacy and safety of R-CHOP in the studied indication.
Approved indications
- B-cell non-Hodgkin lymphoma (specific subtype not specified in available information)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea/vomiting
- Cardiotoxicity
- Infusion reactions
Key clinical trials
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (PHASE3)
- A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (PHASE3)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (PHASE3)
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (PHASE3)
- A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (PHASE3)
- A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (PHASE3)
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ (PHASE3)
- Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |